Braveheart Bio, Inc. BRVE
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | -14.99M | -14.28M | -381.00K | ||
| Total Depreciation and Amortization | 3.00K | 2.00K | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 1.09M | 1.76M | 354.00K | ||
| Change in Net Operating Assets | -3.05M | 7.33M | 27.00K | ||
| Cash from Operations | -16.95M | -5.19M | 0.00 | ||
| Capital Expenditure | 8.00K | -36.00K | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | 0.00 | -3.00M | -- | ||
| Cash from Investing | 8.00K | -3.04M | -- | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | 2.00K | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | 59.60M | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -399.00K | -363.00K | -- | ||
| Cash from Financing | 59.20M | -363.00K | 2.00K | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 42.26M | -8.59M | 2.00K | ||